Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities
Sikander Ailawadhi(Jacksonville College), Asher Chanan‐Khan(WinnMed), Pooja Advani(Jacksonville College), Taimur Sher(Mayo Clinic in Florida), Aneel Paulus(Mayo Clinic), Shahrukh K. Hashmi(Sheikh Shakhbout Medical City), Mayank Sharma(Jacksonville College), Richa Menghani(Jacksonville College), Gerardo Colón‐Otero(Jacksonville College), Nandita Khera(Mayo Clinic in Florida), Shumail M. Paulus(Jacksonville College), M’hamed Temkit(Phoenix Children's Hospital), Vivek Roy(Jacksonville College), Ryan D. Frank(Mayo Clinic), Abhisek Swaika(Jacksonville College), Nabeel Aslam(Jacksonville College)
Cited by 55
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
|Blood|2011|450
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435